Payment overview · 2025
General Payments
$2,159.67
118 reported records · 14 companies
Healthcare provider profile · identity verified
Eddie C Pyune, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · GARDEN GROVE, CA · NPI 1457445124
Verified facts
What the public records show
CMS Open Payments records show Eddie C Pyune, M.D. received $2,159.67 in general payments during 2025 across 118 reported records.
Amgen Inc. accounted for 19.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Edarbi, Farxiga, Gemtesa, Jardiance, Linzess, Prolia, Trelegy Ellipta, Zenpep, Ztlido.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 512 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Synthroid by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 130 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 311 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 227 claims for Farxiga by this doctor in 2024.
Azurity Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EDARBI as an associated drug or biological on 1140 records involving 805 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Edarbi by this doctor in 2024.
Azurity Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EDARBYCLOR as an associated drug or biological on 283 records involving 215 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Edarbyclor by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 341 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 341 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Mounjaro by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Entresto by this doctor in 2024.
SCILEX PHARMACEUTICALS INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZTLido as an associated drug or biological on 6923 records involving 3060 distinct recipient NPIs. Public Medicare Part D data also shows 347 claims for Ztlido by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $424.93 | 19.7% | 30 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $376.34 | 17.4% | 16 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $279.80 | 13.0% | 12 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $252.47 | 11.7% | 13 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $244.79 | 11.3% | 12 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $219.76 | 10.2% | 18 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $104.02 | 4.8% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $64.74 | 3.0% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $46.57 | 2.2% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $46.30 | 2.1% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $35.16 | 1.6% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $29.16 | 1.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.23 | 0.8% | 1 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $17.40 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,159.67 | 118 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $376.34 | 16 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $278.55 | 22 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $252.47 | 13 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $244.79 | 12 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $219.76 | 18 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $157.37 | 6 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $149.40 | 11 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $146.38 | 8 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $133.93 | 10 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $119.86 | 7 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $73.06 | 4 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $67.90 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $48.90 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $46.57 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $46.30 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $39.50 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $35.16 | 1 | 2025 |
Source payment records
|
|||||
| EDARBI Normalized: edarbi |
Drug | Azurity Pharmaceuticals, Inc. | $29.16 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $23.32 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $18.23 | 1 | 2025 |
Source payment records
|
|||||
| ELYXYB - CELECOXIB Normalized: elyxyb celecoxib |
Drug | SCILEX PHARMACEUTICALS INC. | $17.40 | 1 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $17.40 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 512 | exact normalized | Medicare Part D |
| EDARBI edarbi |
2025 | Edarbi | 2024 | 55 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 227 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 121 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 341 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 127 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 311 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 130 | exact normalized | Medicare Part D |
| ZTLido ztlido |
2025 | Ztlido | 2024 | 347 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
512 | 105 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
127 | 26 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
130 | 36 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
311 | 164 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
227 | 38 |
| Azurity Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | EDARBI open payments reported associated product |
CMS Open Payments — General Payments 1140 supporting records · 805 recipient NPIs · example record 1242666830 |
Edarbi · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| Azurity Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | EDARBYCLOR open payments reported associated product |
CMS Open Payments — General Payments 283 supporting records · 215 recipient NPIs · example record 1242666846 |
Edarbyclor · 2024 Exact normalized brand match · 1 Part D row |
76 | 11 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
341 | 46 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
341 | 46 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
79 | 11 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
| SCILEX PHARMACEUTICALS INC. Exact reporting entity; no affiliate inference |
2025 | ZTLido open payments reported associated product |
CMS Open Payments — General Payments 6923 supporting records · 3060 recipient NPIs · example record 1242585247 |
Ztlido · 2024 Exact normalized brand match · 1 Part D row |
347 | 59 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
121 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1022 | 155 |
| Repatha Sureclick | Evolocumab | 838 | 134 |
| Repatha Pushtronex | Evolocumab | 664 | 119 |
| Vascepa | Icosapent Ethyl | 664 | 132 |
| Dexlansoprazole Dr | Dexlansoprazole | 567 | 85 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 529 | 72 |
| Creon | Lipase/Protease/Amylase | 512 | 105 |
| Amlodipine Besylate | Amlodipine Besylate | 480 | 64 |
| Lidocaine | Lidocaine | 413 | 73 |
| Levothyroxine Sodium | Levothyroxine Sodium | 407 | 52 |
| Ztlido | Lidocaine | 347 | 59 |
| Jardiance | Empagliflozin | 341 | 46 |
| Metoprolol Succinate | Metoprolol Succinate | 339 | 46 |
| Prolia | Denosumab | 311 | 164 |
| Icosapent Ethyl | Icosapent Ethyl | 292 | 89 |
| Losartan Potassium | Losartan Potassium | 266 | 47 |
| Montelukast Sodium | Montelukast Sodium | 242 | 44 |
| Farxiga | Dapagliflozin Propanediol | 227 | 38 |
| Diclofenac Sodium | Diclofenac Sodium | 218 | 47 |
| Mirtazapine | Mirtazapine | 217 | 40 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 216 | 58 |
| Pantoprazole Sodium | Pantoprazole Sodium | 215 | 46 |
| Clopidogrel | Clopidogrel Bisulfate | 212 | 25 |
| Azithromycin | Azithromycin | 211 | 130 |
| Furosemide | Furosemide | 208 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 206 | 30 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 195 | 25 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 171 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 168 | 45 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 165 | 22 |
| Gabapentin | Gabapentin | 162 | 27 |
| Glimepiride | Glimepiride | 148 | 19 |
| Atorvastatin Calcium | Atorvastatin Calcium | 146 | 31 |
| Eliquis | Apixaban | 137 | 23 |
| Metformin Hcl | Metformin Hcl | 134 | 23 |
| Zenpep | Lipase/Protease/Amylase | 130 | 36 |
| Linzess | Linaclotide | 127 | 26 |
| Famotidine | Famotidine | 125 | 27 |
| Nebivolol Hcl | Nebivolol Hcl | 123 | 14 |
| Omeprazole | Omeprazole | 123 | 22 |
| Januvia | Sitagliptin Phosphate | 122 | 19 |
| Gemtesa | Vibegron | 121 | 23 |
| Donepezil Hcl | Donepezil Hcl | 116 | 19 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 115 | 16 |
| Alcohol Swabs | Alcohol Antiseptic Pads | 111 | 26 |
| Kerendia | Finerenone | 110 | 16 |
| Tresiba Flextouch U-200 | Insulin Degludec | 108 | 21 |
| Carvedilol | Carvedilol | 107 | 12 |
| Tradjenta | Linagliptin | 106 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 97 | 11 |
| Celecoxib | Celecoxib | 95 | 21 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 94 | 17 |
| Pregabalin | Pregabalin | 94 | 12 |
| Acarbose | Acarbose | 85 | 11 |
| Atenolol | Atenolol | 82 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 80 | 12 |
| Meloxicam | Meloxicam | 79 | 14 |
| Mounjaro | Tirzepatide | 79 | 11 |
| Allopurinol | Allopurinol | 77 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 77 | 20 |
| Azelastine Hcl | Azelastine Hcl | 76 | 21 |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 76 | 11 |
| Dapagliflozin | Dapagliflozin Propanediol | 75 | 21 |
| Nystatin | Nystatin | 74 | 22 |
| Dutasteride | Dutasteride | 73 | 11 |
| Evenity (2 Syringes) | Romosozumab-Aqqg | 69 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 68 | 18 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 65 | 41 |
| Ceftriaxone | Ceftriaxone Sodium | 59 | 50 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 59 | 15 |
| Cilostazol | Cilostazol | 56 | suppressed |
| Entresto | Sacubitril/Valsartan | 56 | suppressed |
| Edarbi | Azilsartan Medoxomil | 55 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 55 | suppressed |
| Lactated Ringers | Ringer's Solution,lactated | 55 | 46 |
| Potassium Chloride | Potassium Chloride | 55 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 54 | 16 |
| Dextrose In Lactated Ringers | Dextrose 5%-Lactated Ringers | 54 | 43 |
| Diphenhydramine Hcl | Diphenhydramine Hcl | 53 | 47 |
| Livalo | Pitavastatin Calcium | 52 | 11 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 51 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 50 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 49 | 11 |
| Rybelsus | Semaglutide | 48 | suppressed |
| Ciclopirox | Ciclopirox | 47 | 13 |
| Paxlovid | Nirmatrelvir/Ritonavir | 47 | 46 |
| Praluent Pen | Alirocumab | 47 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 46 | suppressed |
| Memantine Hcl | Memantine Hcl | 44 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 43 | suppressed |
| Mupirocin | Mupirocin | 43 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 42 | 23 |
| Finasteride | Finasteride | 41 | suppressed |
| Ketoconazole | Ketoconazole | 41 | suppressed |
| Sucralfate | Sucralfate | 40 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 38 | suppressed |
| Clotrimazole | Clotrimazole | 37 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 36 | suppressed |
| Baclofen | Baclofen | 35 | 12 |
| Epinephrine | Epinephrine | 35 | 30 |
| Naproxen | Naproxen | 35 | suppressed |
| Famciclovir | Famciclovir | 34 | 24 |
| Methimazole | Methimazole | 33 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 32 | suppressed |
| Brilinta | Ticagrelor | 31 | suppressed |
| Ramelteon | Ramelteon | 31 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 31 | suppressed |
| Cephalexin | Cephalexin | 30 | 27 |
| Ciclopirox | Ciclopirox Olamine | 30 | suppressed |
| Ranolazine Er | Ranolazine | 30 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 30 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 30 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 28 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 28 | suppressed |
| Procto-Med Hc | Hydrocortisone | 28 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 27 | 13 |
| Hydrocortisone | Hydrocortisone | 27 | suppressed |
| Folic Acid | Folic Acid | 26 | suppressed |
| Myrbetriq | Mirabegron | 26 | suppressed |
| Ssd | Silver Sulfadiazine | 26 | 16 |
| Aripiprazole | Aripiprazole | 25 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 21 |
| Lisinopril | Lisinopril | 24 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 22 | suppressed |
| Gemfibrozil | Gemfibrozil | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Alprazolam | Alprazolam | 21 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | suppressed |
| Prednisone | Prednisone | 21 | suppressed |
| Repatha Syringe | Evolocumab | 21 | suppressed |
| Acyclovir | Acyclovir | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Timolol Maleate | Timolol Maleate | 20 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 20 | suppressed |
| Admelog Solostar | Insulin Lispro | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 15 |
| Dutasteride-Tamsulosin | Dutasteride/Tamsulosin Hcl | 19 | suppressed |
| Fluvastatin Sodium | Fluvastatin Sodium | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 19 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 19 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Methotrexate | Methotrexate Sodium | 17 | suppressed |
| Latanoprost | Latanoprost | 16 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 16 | suppressed |
| Fluocinonide | Fluocinonide | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | 12 |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 14 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 14 | 13 |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Ezetimibe | Ezetimibe | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Jentadueto Xr | Linagliptin/Metformin Hcl | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Rivastigmine | Rivastigmine | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Ursodiol | Ursodiol | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Exelon | Rivastigmine | 11 | suppressed |
| Simvastatin | Simvastatin | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 11 | suppressed |
| Voquezna | Vonoprazan Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,159.67 · 118 records | Amgen Inc. | AIRSUPRA, BREZTRI, CREON, Dexcom G6 Transmitter, EDARBI, ELYXYB - CELECOXIB, EVENITY, FARXIGA, FASENRA, GEMTESA, IBSRELA, JARDIANCE, KISUNLA, LEQVIO, LINZESS, OTEZLA, PROLIA, REPATHA, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, ZENPEP, ZTLido | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error